The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Three Year Phase IIB Grant Entitled "Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT"

 

Doylestown, PA. September 11, 2019 - FCCDC is pleased to announce that it has received a 3-yr NHLBI SBIR Phase IIB Small Market Award to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases, entitled "Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT" (R44HL123126), which represents a public-private partnership between the New York Blood Center, Thomas Jefferson University and FCCDC.